메뉴 건너뛰기




Volumn 93, Issue 1, 2013, Pages 78-85

Emerging target-based paradigms to prevent and treat migraine

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; CALCITONIN GENE RELATED PEPTIDE; ELETRIPTAN; ERGOT DERIVATIVE; FROVATRIPTAN; NARATRIPTAN; PLASMA PROTEIN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUBSTANCE P; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

EID: 84871261412     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.198     Document Type: Article
Times cited : (64)

References (79)
  • 1
    • 0001694653 scopus 로고    scopus 로고
    • Migraine: Diagnosis and treatment
    • 7th edn. (eds. Silberstein, S.D., Lipton, R.B. & Dalessio, D.J. Oxford University Press, New York 2001
    • Silberstein, S.D., Saper, J.R. & Freitag, F. Migraine: Diagnosis and treatment. In Wolff's Headache and Other Head Pain 7th edn. (eds. Silberstein, S.D., Lipton, R.B. & Dalessio, D.J.) 121-237 (Oxford University Press, New York, 2001).
    • Wolff's Headache and Other Head Pain , pp. 121-237
    • Silberstein, S.D.1    Saper, J.R.2    Freitag, F.3
  • 2
    • 0345671971 scopus 로고    scopus 로고
    • The international classification of headache disorders 2nd edn
    • Headache Classification Committee
    • Headache Classification Committee. The International Classification of Headache Disorders 2nd edn. Cephalalgia 24, 1-160 (2004).
    • (2004) Cephalalgia , vol.24 , pp. 1-160
  • 3
    • 0026529131 scopus 로고
    • Prevalence of migraine headache in the United States Relation to age, income, race, and other sociodemographic factors
    • Stewart, W.F., Lipton, R.B., Celentano, D.D. & Reed, M.L. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267, 64-69 (1992).
    • (1992) JAMA , vol.267 , pp. 64-69
    • Stewart, W.F.1    Lipton, R.B.2    Celentano, D.D.3    Reed, M.L.4
  • 4
    • 0029988603 scopus 로고    scopus 로고
    • A nosographic analysis of the migraine aura in a general population
    • Pt 2
    • Russell, M.B. & Olesen, J. A nosographic analysis of the migraine aura in a general population. Brain 119 (Pt 2), 355-361 (1996).
    • (1996) Brain , vol.119 , pp. 355-361
    • Russell, M.B.1    Olesen, J.2
  • 5
    • 0028452080 scopus 로고
    • Migraine heterogeneity disability, pain intensity, and attack frequency and duration
    • Stewart, W.F., Shechter, A. & Lipton, R.B. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 44, S24-S39 (1994).
    • (1994) Neurology , vol.44
    • Stewart, W.F.1    Shechter, A.2    Lipton, R.B.3
  • 6
    • 0029120324 scopus 로고
    • Migraine symptoms: Results of a survey of self-reported migraineurs
    • Silberstein, S.D. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache 35, 387-396 (1995).
    • (1995) Headache , vol.35 , pp. 387-396
    • Silberstein, S.D.1
  • 8
    • 33745184401 scopus 로고    scopus 로고
    • New appendix criteria open for a broader concept of chronic migraine
    • Headache Classification Committee
    • Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006).
    • (2006) Cephalalgia , vol.26 , pp. 742-746
  • 9
    • 0037165257 scopus 로고    scopus 로고
    • Migraine-current understanding and treatment
    • Goadsby, P.J., Lipton, R.B. & Ferrari, M.D. Migraine-current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
    • (2002) N. Engl. J. Med , vol.346 , pp. 257-270
    • Goadsby, P.J.1    Lipton, R.B.2    Ferrari, M.D.3
  • 10
    • 0001099704 scopus 로고
    • Spreading depression of activity in cerebral cortex
    • Leao, A.A.P. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
    • (1944) J. Neurophysiol , vol.7 , pp. 359-390
    • Leao, A.A.P.1
  • 11
    • 0025690295 scopus 로고
    • Timing and topography of cerebral blood flow, aura, and headache during migraine attacks
    • Olesen, J. et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28, 791-798 (1990).
    • (1990) Ann. Neurol , vol.28 , pp. 791-798
    • Olesen, J.1
  • 12
    • 0026505310 scopus 로고
    • Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation
    • Dimitriadou, V., Buzzi, M.G., Theoharides, T.C. & Moskowitz, M.A. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48, 187-203 (1992).
    • (1992) Neuroscience , vol.48 , pp. 187-203
    • Dimitriadou, V.1    Buzzi, M.G.2    Theoharides, T.C.3    Moskowitz, M.A.4
  • 13
    • 0037627980 scopus 로고    scopus 로고
    • Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice
    • Kandere-Grzybowska, K. et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res. 980, 213-220 (2003).
    • (2003) Brain Res , vol.980 , pp. 213-220
    • Kandere-Grzybowska, K.1
  • 15
    • 3142548079 scopus 로고
    • Why study the comorbidity of migraine?
    • Lipton, R.B. & Silberstein, S.D. Why study the comorbidity of migraine? Neurology 44, S4-S5 (1994).
    • (1994) Neurology , vol.44
    • Lipton, R.B.1    Silberstein, S.D.2
  • 16
    • 0842274187 scopus 로고    scopus 로고
    • Sumatriptan treats the full spectrum of headache in individuals with disabling IHS migraine
    • Lipton, R.B., Cady, R.K., O'Quinn, S., Hall, C.B. & Stewart, W.F. Sumatriptan treats the full spectrum of headache in individuals with disabling IHS migraine. Headache 40, 783-791 (1999).
    • (1999) Headache , vol.40 , pp. 783-791
    • Lipton, R.B.1    Cady, R.K.2    O'Quinn, S.3    Hall, C.B.4    Stewart, W.F.5
  • 17
    • 0006386574 scopus 로고    scopus 로고
    • Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks
    • Matchar, D.B. et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Neurology (2000).
    • (2000) Neurology
    • Matchar, D.B.1
  • 18
    • 0033916915 scopus 로고    scopus 로고
    • Cardiac risk factors and the use of triptans: A survey study
    • Y oung, W.B., Mannix, L., Adelman, J.U. & Shechter, A.L. Cardiac risk factors and the use of triptans: A survey study. Headache 40, 587-591 (2000).
    • (2000) Headache , vol.40 , pp. 587-591
    • Young, W.B.1    Mannix, L.2    Adelman, J.U.3    Shechter, A.L.4
  • 19
    • 0028183017 scopus 로고
    • International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)
    • Hoyer, D. et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157-203 (1994).
    • (1994) Pharmacol. Rev , vol.46 , pp. 157-203
    • Hoyer, D.1
  • 20
    • 0029930933 scopus 로고    scopus 로고
    • Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes
    • Hartig, P.R., Hoyer, D., Humphrey, P.P. & Martin, G.R. Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes. Trends Pharmacol. Sci. 17, 103-105 (1996).
    • (1996) Trends Pharmacol. Sci , vol.17 , pp. 103-105
    • Hartig, P.R.1    Hoyer, D.2    Humphrey, P.P.3    Martin, G.R.4
  • 21
    • 0031283073 scopus 로고    scopus 로고
    • Differential distribution of 5HT1D- and 5HT1Bimmunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs
    • Longmore, J. et al. Differential distribution of 5HT1D- and 5HT1Bimmunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalalgia 17, 833-842 (1997).
    • (1997) Cephalalgia , vol.17 , pp. 833-842
    • Longmore, J.1
  • 22
    • 1642569727 scopus 로고    scopus 로고
    • Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists
    • Levy, D., Jakubowski, M. & Burstein, R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc. Natl. Acad. Sci. USA 101, 4274-4279 (2004).
    • (2004) Proc. Natl. Acad. Sci. USA , vol.101 , pp. 4274-4279
    • Levy, D.1    Jakubowski, M.2    Burstein, R.3
  • 23
    • 0027419370 scopus 로고
    • Clinical and experimental effects of sumatriptan in humans
    • Ferrari, M.D. & Saxena, P.R. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 14, 129-133 (1993).
    • (1993) Trends Pharmacol. Sci , vol.14 , pp. 129-133
    • Ferrari, M.D.1    Saxena, P.R.2
  • 24
    • 0026056238 scopus 로고
    • Mode of action of the anti-migraine drug sumatriptan
    • Humphrey, P.P. & Feniuk, W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol. Sci. 12, 444-446 (1991).
    • (1991) Trends Pharmacol. Sci , vol.12 , pp. 444-446
    • Humphrey, P.P.1    Feniuk, W.2
  • 25
    • 0034519937 scopus 로고    scopus 로고
    • Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study
    • Lipton, R.B. et al. Sumatriptan for the range of headaches in migraine sufferers: Results of the spectrum study. Headache 40, 783-791 (2000).
    • (2000) Headache , vol.40 , pp. 783-791
    • Lipton, R.B.1
  • 26
    • 85038904297 scopus 로고    scopus 로고
    • In Wolff's Headache and Other Head Pain 8th edn. (eds. Silberstein, S.D., Lipton, R.B., Dodick, D.W. Oxford University Press, New York
    • Silberstein, S.D., Freitag, F.G. & Bigal, M.E. Migraine treatment. In Wolff's Headache and Other Head Pain 8th edn. (eds. Silberstein, S.D., Lipton, R.B., Dodick, D.W.) 177-292 (Oxford University Press, New York, 2008).
    • (2008) Migraine Treatment , pp. 177-292
    • Silberstein, S.D.1    Freitag, F.G.2    Bigal, M.E.3
  • 27
    • 0038211995 scopus 로고    scopus 로고
    • Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: Clinical and preclinical evidence [abstr.]
    • Burstein, R., Collins, B., Bajwa, Z. & Jakubowski, M. Triptan therapy can abort migraine attacks if given before the establishment or in the absence of cutaneous allodynia and central sensitization: Clinical and preclinical evidence [abstr.]. Headache 42, 390-391 (2002).
    • (2002) Headache , vol.42 , pp. 390-391
    • Burstein, R.1    Collins, B.2    Bajwa, Z.3    Jakubowski, M.4
  • 28
    • 0033810275 scopus 로고    scopus 로고
    • Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials
    • Cady, R.K. et al. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin. Ther. 22, 1035-1048 (2000).
    • (2000) Clin. Ther , vol.22 , pp. 1035-1048
    • Cady, R.K.1
  • 29
    • 0030610869 scopus 로고    scopus 로고
    • Cloning and characterization of the guinea pig 5-HT1F receptor subtype: A comparison of the pharmacological profile to the human species homolog
    • Adham, N. et al. Cloning and characterization of the guinea pig 5-HT1F receptor subtype: A comparison of the pharmacological profile to the human species homolog. Neuropharmacology 36, 569-576 (1997).
    • (1997) Neuropharmacology , vol.36 , pp. 569-576
    • Adham, N.1
  • 30
    • 79551688567 scopus 로고    scopus 로고
    • Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan
    • Nelson, D.L. et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30, 1159-1169 (2010).
    • (2010) Cephalalgia , vol.30 , pp. 1159-1169
    • Nelson, D.L.1
  • 31
    • 84859812075 scopus 로고    scopus 로고
    • Efficacy and tolerability of lasmiditan, an oral 5-HT(1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
    • Farkkila, M. et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 11, 405-413 (2012).
    • (2012) Lancet Neurol , vol.11 , pp. 405-413
    • Farkkila, M.1
  • 32
    • 0023874663 scopus 로고
    • Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
    • Goadsby, P.J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193-196 (1988).
    • (1988) Ann. Neurol , vol.23 , pp. 193-196
    • Goadsby, P.J.1    Edvinsson, L.2    Ekman, R.3
  • 33
    • 0023874663 scopus 로고
    • Release of vasoactive peptides in the extracerebral circulation of man
    • Goadsby, P.J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of man. Ann. Neurol. 23, 193-196 (1988).
    • (1988) Ann. Neurol , vol.23 , pp. 193-196
    • Goadsby, P.J.1    Edvinsson, L.2    Ekman, R.3
  • 34
    • 0025143541 scopus 로고
    • Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
    • Goadsby, P.J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183-187 (1990).
    • (1990) Ann. Neurol , vol.28 , pp. 183-187
    • Goadsby, P.J.1    Edvinsson, L.2    Ekman, R.3
  • 36
    • 0001371622 scopus 로고    scopus 로고
    • Substance-P antagonist RPR100893-201 is not effective in human migraine attacks
    • eds. Olesen, J. and Tfelt-Hansen, P. Lippincott-Raven, New York
    • Diener, H.C. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In Proceedings of the VIth International Headache Seminar (eds. Olesen, J. and Tfelt-Hansen, P.) (Lippincott-Raven, New York, 1996).
    • (1996) Proceedings of the VIth International Headache Seminar
    • Diener, H.C.1
  • 37
    • 0000128214 scopus 로고    scopus 로고
    • A placebo-controlled in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754 030) in the acute treatment of migraine
    • Norman, B., Panebianco, D. & Block, G.A. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalalgia 18, 407 (1998).
    • (1998) Cephalalgia , vol.18 , pp. 407
    • Norman, B.1    Panebianco, D.2    Block, G.A.3
  • 38
    • 0021857460 scopus 로고
    • Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide
    • Amara, S.G., Arriza, J.L., Leff, S.E., Swanson, L.W., Evans, R.M. & Rosenfeld, M.G. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229, 1094-1097 (1985).
    • (1985) Science , vol.229 , pp. 1094-1097
    • Amara, S.G.1    Arriza, J.L.2    Leff, S.E.3    Swanson, L.W.4    Evans, R.M.5    Rosenfeld, M.G.6
  • 39
    • 0036266044 scopus 로고    scopus 로고
    • International Union of Pharmacology XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors
    • Poyner, D.R. et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54, 233-246 (2002).
    • (2002) Pharmacol. Rev , vol.54 , pp. 233-246
    • Poyner, D.R.1
  • 41
    • 1542346238 scopus 로고    scopus 로고
    • Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
    • Olesen, J. et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350, 1104-1110 (2004).
    • (2004) N. Engl. J. Med , vol.350 , pp. 1104-1110
    • Olesen, J.1
  • 42
    • 42249087655 scopus 로고    scopus 로고
    • Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    • Ho, T.W. et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312 (2008).
    • (2008) Neurology , vol.70 , pp. 1304-1312
    • Ho, T.W.1
  • 43
    • 57649233374 scopus 로고    scopus 로고
    • Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, paralleltreatment trial
    • Ho, T.W. et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, paralleltreatment trial. Lancet 372, 2115-2123 (2008).
    • (2008) Lancet , vol.372 , pp. 2115-2123
    • Ho, T.W.1
  • 44
    • 70349682469 scopus 로고    scopus 로고
    • Randomized, controlled trial of telcagepant for the acute treatment of migraine
    • Connor, K.M. et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73, 970-977 (2009).
    • (2009) Neurology , vol.73 , pp. 970-977
    • Connor, K.M.1
  • 45
    • 78650963413 scopus 로고    scopus 로고
    • Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine
    • Tfelt-Hansen, P. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine. Headache 51, 118-123 (2011).
    • (2011) Headache , vol.51 , pp. 118-123
    • Tfelt-Hansen, P.1
  • 46
    • 71049116463 scopus 로고    scopus 로고
    • Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines
    • Burgey, C.S. et al. Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines. Bioorg. Med. Chem. Lett. 19, 6368-6372 (2009).
    • (2009) Bioorg. Med. Chem. Lett , vol.19 , pp. 6368-6372
    • Burgey, C.S.1
  • 47
    • 79953220801 scopus 로고    scopus 로고
    • BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
    • Diener, H.C., Barbanti, P., Dahlof, C., Reuter, U., Habeck, J. & Podhorna, J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia 31, 573-584 (2011).
    • (2011) Cephalalgia , vol.31 , pp. 573-584
    • Diener, H.C.1    Barbanti, P.2    Dahlof, C.3    Reuter, U.4    Habeck, J.5    Podhorna, J.6
  • 48
    • 84859771560 scopus 로고    scopus 로고
    • Discovery of BMS-846372, a potent and orally active human CGRP receptor agonist for the treatment of migraine
    • Luo, G. et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor agonist for the treatment of migraine. Med. Chem. Lett. 3, 337-341 (2012).
    • (2012) Med. Chem. Lett , vol.3 , pp. 337-341
    • Luo, G.1
  • 49
    • 0027224036 scopus 로고
    • Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain
    • Olesen, J., Iversen, H.K. & Thomsen, L.L. Nitric oxide supersensitivity: A possible molecular mechanism of migraine pain. Neuroreport 4, 1027-1030 (1993).
    • (1993) Neuroreport , vol.4 , pp. 1027-1030
    • Olesen, J.1    Iversen, H.K.2    Thomsen, L.L.3
  • 51
    • 0026760948 scopus 로고
    • A novel neuronal messenger molecule in brain: The free radical, nitric oxide
    • Dawson, T.M., Dawson, V.L. & Snyder, S.H. A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Ann. Neurol. 32, 297-311 (1992).
    • (1992) Ann. Neurol , vol.32 , pp. 297-311
    • Dawson, T.M.1    Dawson, V.L.2    Snyder, S.H.3
  • 52
    • 0027314739 scopus 로고
    • Regulation of the cerebral microcirculation during neural activity: Is nitric oxide the missing link
    • Ladecola, C. Regulation of the cerebral microcirculation during neural activity: Is nitric oxide the missing link? TiPS 16, 206-214 (1993).
    • (1993) TiPS , vol.16 , pp. 206-214
    • Ladecola, C.1
  • 54
    • 21244458471 scopus 로고    scopus 로고
    • GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo
    • Alderton, W.K. et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 145, 301-312 (2005).
    • (2005) Br. J. Pharmacol , vol.145 , pp. 301-312
    • Alderton, W.K.1
  • 55
    • 30444458848 scopus 로고    scopus 로고
    • GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain
    • De Alba, J., Clayton, N.M., Collins, S.D., Colthup, P., Chessell, I. & Knowles, R.G. GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain 120, 170-181 (2006).
    • (2006) Pain , vol.120 , pp. 170-181
    • De Alba, J.1    Clayton, N.M.2    Collins, S.D.3    Colthup, P.4    Chessell, I.5    Knowles, R.G.6
  • 57
    • 79952460799 scopus 로고    scopus 로고
    • Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache
    • Hoivik, H.O. et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 30, 1458-1467 (2010).
    • (2010) Cephalalgia , vol.30 , pp. 1458-1467
    • Hoivik, H.O.1
  • 58
    • 61849143554 scopus 로고    scopus 로고
    • Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine [abstr]
    • Hoye K., Laurijssens B.E., Harnisch L.O., Twomey C.K., Dixon R.M. & Kirkham A. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine [abstr]. Cephalalgia 29,132 (2009).
    • (2009) Cephalalgia , vol.29 , pp. 132
    • Hoye, K.1    Laurijssens, B.E.2    Harnisch, L.O.3    Twomey, C.K.4    Dixon, R.M.5    Kirkham, A.6
  • 59
    • 79957762234 scopus 로고    scopus 로고
    • Emerging migraine treatments and drug targets
    • Olesen, J. & Ashina, M. Emerging migraine treatments and drug targets. Trends Pharmacol. Sci. 32, 352-359 (2011).
    • (2011) Trends Pharmacol. Sci , vol.32 , pp. 352-359
    • Olesen, J.1    Ashina, M.2
  • 60
    • 47649114235 scopus 로고    scopus 로고
    • Roles of TRESK a novel two-pore domain K+ channel, in pain pathway and general anesthesia
    • Huang, D.Y., Yu, B.W. & Fan, Q.W. Roles of TRESK, a novel two-pore domain K+channel, in pain pathway and general anesthesia. Neurosci. Bull. 24, 166-172 (2008).
    • (2008) Neurosci. Bull , vol.24 , pp. 166-172
    • Huang, D.Y.1    Yu, B.W.2    Fan, Q.W.3
  • 61
    • 77951041210 scopus 로고    scopus 로고
    • Molecular background of leak K+ currents: Two-pore domain potassium channels
    • Enyedi, P. & Czirjak, G. Molecular background of leak K+ currents: Two-pore domain potassium channels. Physiol. Rev. 90, 559-605 (2010).
    • (2010) Physiol. Rev , vol.90 , pp. 559-605
    • Enyedi, P.1    Czirjak, G.2
  • 62
    • 9244228006 scopus 로고    scopus 로고
    • Potent activation of the human tandem pore domain K channel TRESK with clinical concentrations of volatile anesthetics
    • table of contents
    • Liu, C., Au, J.D., Zou, H.L., Cotten, J.F. & Yost, C.S. Potent activation of the human tandem pore domain K channel TRESK with clinical concentrations of volatile anesthetics. Anesth. Analg. 99, 1715-1722, table of contents (2004).
    • (2004) Anesth. Analg , vol.99 , pp. 1715-1722
    • Liu, C.1    Au, J.D.2    Zou, H.L.3    Cotten, J.F.4    Yost, C.S.5
  • 63
    • 2442511134 scopus 로고    scopus 로고
    • The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin
    • Czirjak, G., Toth, Z.E. & Enyedi, P. The two-pore domain K+ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin. J. Biol. Chem. 279, 18550-18558 (2004).
    • (2004) J. Biol. Chem , vol.279 , pp. 18550-18558
    • Czirjak, G.1    Toth, Z.E.2    Enyedi, P.3
  • 64
    • 33846198311 scopus 로고    scopus 로고
    • Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors
    • Mathie, A. Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors. J. Physiol. (Lond.) 578, 377-385 (2007).
    • (2007) J. Physiol. (Lond , vol.578 , pp. 377-385
    • Mathie, A.1
  • 65
    • 70350441843 scopus 로고    scopus 로고
    • Calcineurin as a nociceptor modulator
    • Smith, H.S. Calcineurin as a nociceptor modulator. Pain Physician 12, E309-E318 (2009).
    • (2009) Pain Physician , vol.12
    • Smith, H.S.1
  • 66
    • 77957812064 scopus 로고    scopus 로고
    • A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
    • Lafreniere, R.G. et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat. Med. 16, 1157-1160 (2010).
    • (2010) Nat. Med , vol.16 , pp. 1157-1160
    • Lafreniere, R.G.1
  • 67
    • 0036727675 scopus 로고    scopus 로고
    • Migraine: Preventive treatment
    • Silberstein, S.D. & Goadsby, P.J. Migraine: Preventive treatment. Cephalalgia 22, 491-512 (2002).
    • (2002) Cephalalgia , vol.22 , pp. 491-512
    • Silberstein, S.D.1    Goadsby, P.J.2
  • 68
    • 0037345762 scopus 로고    scopus 로고
    • Migraine preventive medication reduces resource utilization
    • Silberstein, S.D., Winner, P.K. & Chmiel, J.J. Migraine preventive medication reduces resource utilization. Headache 43, 171-178 (2003).
    • (2003) Headache , vol.43 , pp. 171-178
    • Silberstein, S.D.1    Winner, P.K.2    Chmiel, J.J.3
  • 69
    • 0345240153 scopus 로고    scopus 로고
    • Evidence-based Guidelines Of The Pharmacological Management For Prevention Of Migraine For The Primary Care Provider
    • Ramadan, N.M., Silberstein, S.D., Freitag, F.G., Gilbert, T.T. & Frishberg, B. Evidence-based guidelines of the pharmacological management for prevention of migraine for the primary care provider. Neurology (1999).
    • (1999) Neurology
    • Ramadan, N.M.1    Silberstein, S.D.2    Freitag, F.G.3    Gilbert, T.T.4    Frishberg, B.5
  • 70
    • 84860767840 scopus 로고    scopus 로고
    • Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
    • Silberstein, S.D., Holland, S., Freitag, F., Dodick, D.W., Argoff, C. & Ashman, E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1337-1345 (2012).
    • (2012) Neurology , vol.78 , pp. 1337-1345
    • Silberstein, S.D.1    Holland, S.2    Freitag, F.3    Dodick, D.W.4    Argoff, C.5    Ashman, E.6
  • 71
    • 36249025767 scopus 로고    scopus 로고
    • Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial
    • Diener, H.C. et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 6, 1054-1062 (2007).
    • (2007) Lancet Neurol , vol.6 , pp. 1054-1062
    • Diener, H.C.1
  • 72
    • 84893454585 scopus 로고    scopus 로고
    • A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys
    • Los Angeles, CA, 21 June
    • Zhu, D.X.D. et al. A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys. American Headache Society 54th Annual Scientific Meeting, Los Angeles, CA, 21 June 2012
    • (2012) American Headache Society 54th Annual Scientific Meeting
    • Zhu, D.X.D.1
  • 73
    • 84929610251 scopus 로고    scopus 로고
    • Immunohistochemical localization of the CLR/RAMP1 receptor complex in the trigeminovascular system of the cynomolgus monkey
    • Liu, H. et al. Immunohistochemical localization of the CLR/RAMP1 receptor complex in the trigeminovascular system of the cynomolgus monkey. Headache 51, 6 (2011).
    • Headache , vol.51 , Issue.6 , pp. 2011
    • Liu, H.1
  • 74
    • 56749176453 scopus 로고    scopus 로고
    • CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
    • Zeller, J. et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol. 155, 1093-1103 (2008).
    • (2008) Br. J. Pharmacol , vol.155 , pp. 1093-1103
    • Zeller, J.1
  • 75
    • 0027265899 scopus 로고
    • Monoclonal antibody to rat alpha-CGRP: Production, characterization, and in vivo immunoneutralization activity
    • Wong, H.C. et al. Monoclonal antibody to rat alpha-CGRP: Production, characterization, and in vivo immunoneutralization activity. Hybridoma 12, 93-106 (1993).
    • (1993) Hybridoma , vol.12 , pp. 93-106
    • Wong, H.C.1
  • 76
    • 0035904760 scopus 로고    scopus 로고
    • Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials
    • Ferrari, M.D., Roon, K.I., Lipton, R.B. & Goadsby, P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
    • (2001) Lancet , vol.358 , pp. 1668-1675
    • Ferrari, M.D.1    Roon, K.I.2    Lipton, R.B.3    Goadsby, P.J.4
  • 77
    • 0031760112 scopus 로고    scopus 로고
    • Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
    • Tfelt-Hansen, P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 18, 532-538 (1998).
    • (1998) Cephalalgia , vol.18 , pp. 532-538
    • Tfelt-Hansen, P.1
  • 79
    • 0032907627 scopus 로고    scopus 로고
    • Rizatriptan: A new 5-HT1B/1D receptor agonist for the treatment of migraine
    • Dahlof, C. & Lines, C. Rizatriptan: A new 5-HT1B/1D receptor agonist for the treatment of migraine. Expert Opin. Investig. Drugs 8, 671-685 (1999).
    • (1999) Expert Opin. Investig. Drugs , vol.8 , pp. 671-685
    • Dahlof, C.1    Lines, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.